Compass Therapeutics, Inc.
CMPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6,455.5% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,808.8% | – | – | – |
| EPS Diluted | -0.36 | -0.33 | -0.35 | -1.31 |
| % Growth | -9.1% | 5.7% | 73.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |